Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Investigational Drug Treatment Study for Patients with Selected Solid Tumors
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors.
PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001
PROBODY is a trademark of CytomX Therapeutics, Inc.
In order to participate you must meet the following criteria:
- Have histologically confirmed diagnosis of metastatic or locally advanced unresectable tumors.
- Demonstrate disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment.
- Agree to provide mandatory archival tissue or fresh biopsy.
- Are at least 18 years of age.
This is a partial list of elgibility requirements.